<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659593</url>
  </required_header>
  <id_info>
    <org_study_id>PROCOG-SEP</org_study_id>
    <nct_id>NCT01659593</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients</brief_title>
  <acronym>PROCOG-SEP</acronym>
  <official_title>Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients. A Double Blind Randomized Multicenter Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive disorders are well-known in multiple sclerosis (MS), even in earlier stages of the
      disease. They effect personal life. Their management may be overlooked. The evidence-based
      program proposes exercises to both stimulate preserved functions and develop new abilities
      compensating for cognitive disabilities.

      Aim of the study is to evaluate the efficiency of the remedial program (PROCOG-SEP) designed
      for MS patients, compared to an interactive discussion program(DISINT) 140 multiple sclerosis
      patients will be randomly assigned in one the program for 13 sessions over a 6-month period.

      Main outcome criteria is evolution of SRT-LIST before and after program.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cognitive function measured by SRT-List score</measure>
    <time_frame>0-9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life measured by MusiQol</measure>
    <time_frame>0 -9 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>cognitive function: verbal memory (SRT), visuospatial memory (10/36), verbal fluency (animal categories),empans, code ,DO80, cognitive complaint</measure>
    <time_frame>0-9 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cognitive Disorders</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>procog</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cognitive remedial program 13 sessions over a 6-month period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DISINT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Interactive discussion program of 13 group sessions in a 6-month period</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>procog</intervention_name>
    <description>3 to 5 people group program</description>
    <arm_group_label>procog</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>DISINT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 ≤Aged ≤ 60 at baseline

          -  Must be able to understand and read french language

          -  Must sign the informed consent form

          -  Must be affiliate to French social security

          -  multiple sclerosis confirmed by Mac Donald criteria

          -  EDSS ≤ 6.0 at baseline

          -  Duration of multiple sclerosis ≤ 30 years at baseline

          -  mild cognitive disorder ( at least 2 cognitive tasks, at most 5 )

        Exclusion Criteria:

          -  under legal protection

          -  treatment by corticosteroids in the past 4 weeks

          -  cognitive remedial program already done

          -  neuropsychologic assessment in the past 2 months

          -  having an other chronic disease

          -  having an other neurologic disease

          -  alcohol or drug addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc DEBOUVERIE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU NANCY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric BERGER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de BESANCON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thibaut MOREAU, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jérôme de Sèze, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de STRASBOURG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc DEBOUVERIE, MD</last_name>
      <phone>00 33 3 83 15 16 88</phone>
      <email>m.debouverie@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Debouverie, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2012</study_first_submitted>
  <study_first_submitted_qc>August 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2012</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive disorders</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>neuropsychology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

